1. Canada Stocks

  2. •

    Healthcare

  3. •

    Drug Manufacturers - Specialty & Generic
PharmaCielo Ltd.

PharmaCielo Ltd.

PCLO.V
PharmaCielo Ltd.CA flagToronto Stock Exchange Ventures
0.08
CAD
+0.00
- -
14.10MMarket Cap
PharmaCielo Ltd.
PCLO.V
(Toronto Stock Exchange Ventures)

Recent

price

0.08

P/E

ratio

- -

div

yld

- -

ROIC.AI

2017
2018
2019
2020
2021
2022
2023
2024
TTM
FRC
- -
- -
0.01
0.02
0.01
0.04
0.01
- -
0.02
Revenue per Share
- -
-1.18
-0.36
-0.39
-0.18
-0.1
-0.1
- -
-0.05
Basic EPS, GAAP
- -
-0.64
-0.37
-0.25
-0.15
-0.07
-0.03
- -
-0.01
Free Cash Flow per Basic Share
- -
- -
- -
- -
- -
- -
- -
- -
- -
Dividend per Share
- -
1.06
0.2
-0.03
-0.08
-0.14
-0.2
- -
-0.24
Book Value per Share
- -
1.52
0.45
0.23
0.13
0.04
-0.01
- -
-0.04
Tangible Book Value per Share
- -
- -
96
113
146
151
160
- -
171
Basic Weighted Avg Shares
- -
- -
1
3
2
5
2
3
3
Sales/Revenue/Turnover
- -
- -
-4,362.67
-1,635.17
-1,295.31
-215.4
-651.38
-140.87
-140.87
Operating Margin (%)
- -
- -
1
2
1
2
1
1
1
Depreciation Expense
- -
- -
-35
-44
-27
-15
-16
-9
-9
Net Income, GAAP
- -
- -
- -
- -
- -
- -
- -
- -
- -
Effective Tax Rate (%)
- -
- -
-4,405.55
-1,648.73
-1,369.14
-273.45
-1,057.09
-262.7
-262.7
Profit Margin (%)
- -
- -
16
- -
1
-3
-18
-19
-19
Working Capital
- -
- -
1
4
8
12
3
5
5
LT Debt
- -
- -
45
26
19
6
-2
-8
-8
Total Equity
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Invested Capital (%)
- -
- -
- -
- -
- -
- -
- -
- -
- -
Return on Capital (%)
- -
-131.2
-356.58
- -
- -
- -
- -
- -
- -
Return on Common Equity (%)

Capital Structure

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
ST Debt
16
16
16
LT Borrowings
4
4
5
LT Finance Leases
- -
- -
- -
Preferred Equity and Hybrid Capital
- -
- -
- -
Shares Outstanding
170
170
176
Market Capitalization
26
30
14

Working Capital

FRC

•

in mil. unless spec.
Jun'24
Sep'24
Dec'24
Total Current Assets
3
3
2
Cash, Cash Equivalents & STI
- -
- -
- -
Accounts Receivable, Net
- -
1
- -
Inventories
2
2
2
Total Current Liabilities
22
23
21
Payables & Accruals
6
6
5
ST Debt
16
16
16
Deferred Revenue
- -
- -
- -

Growth Rates

FRC

•

in mil. unless spec.

(avg. rate of change)

10 years
5 years
1 year
Total Equity
- -
17.13%
347.49%
Free Cash Flow
- -
-41.91%
-61.87%
Net Income, GAAP
- -
-18.01%
-43.91%
Sales/Revenue/Turnover
- -
87.64%
125.7%
Total Cash Common Dividend
- -
- -
- -

Quarterly Revenue

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
1
- -
- -
- -
2
2024
- -
1
1
1
3
2025
1
1
- -
- -
- -

Quarterly Earnings Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
-0.02
-0.02
-0.02
-0.04
-0.1
2024
-0.01
-0.02
-0.02
-0.01
- -
2025
-0.01
- -
- -
- -
- -

Quarterly Dividends Per Share

FRC

•

in mil. unless spec.

Year

Q1
Q2
Q3
Q4
FY
2023
- -
- -
- -
- -
- -
2024
- -
- -
- -
- -
- -
2025
- -
- -
- -
- -
- -
Similar Companies
4Cable TV International, Inc. (CATV)
Clever Leaves Holdings Inc. (CLVR)
AstraZeneca Pharma India Limited (ASTRAZEN.BO)
DRI Healthcare Trust (DHT-UN.TO)
Panaxia Labs Israel Ltd (PNAX.TA)
Shandong Lukang Pharmaceutical Co.,Ltd. (600789.SS)
Business
PharmaCielo Ltd. engages in the ethical and sustainable cultivation, processing, and supply of medicinal-grade cannabis products. The company produces medicinal-grade dried cannabis flower, cannabis oil extracts, tetrahydrocannabinol (THC) and cannabidiol (CBD) medical cannabis, and other related products, alongside telemedicine software solutions. PharmaCielo primarily serves health and wellness product manufacturers, pharmacies, medical clinics, and cosmetic companies across multiple global markets, including Canada, Latin America, Africa, and emerging Asian markets. The company operates through its subsidiary PharmaCielo Colombia Holdings S.A.S. and is headquartered in Toronto, Canada. PharmaCielo recently achieved significant sales growth, notably a 143% year-over-year increase resulting in a total revenue of CAD 3.54 million for the fiscal year ending 2024, accompanied by improved gross profit margins and adjusted EBITDA gains due to a more diverse customer base and cost reductions. Key strategic developments include a binding letter of intent to acquire Siam Ventures, a contract manufacturing business based in Thailand, which establishes PharmaCielo’s entry into large Asian markets and broadens its manufacturing capabilities. The company's board will be strengthened by the addition of Siam Ventures' Chairman and CEO post-acquisition. Furthermore, PharmaCielo formed a strategic partnership with Benuvia Operations, LLC to produce current Good Manufacturing Practice (cGMP) and European Union-Good Manufacturing Practice (EU-GMP) pharmaceutical-grade active pharmaceutical ingredients (APIs), enabling expansion into global pharmaceutical markets such as Brazil, Australia, Europe, and the United States. Additional recent operational updates include the completion of the sale of its La Margarita land asset to repay a significant loan and strengthen its balance sheet, allowing focus on high-value sales pipeline expansion. PharmaCielo’s product distribution has extended to 12 countries, including first shipments to Morocco, providing entry into African and broader international markets. Founded in 2014, the company continues to build on its position as a premier global supplier of pharmaceutical-grade cannabis extracts, with ongoing efforts to broaden its product portfolio beyond CBD isolate and to meet increasing global demand for reliable, high-quality medicinal cannabis products.

Company News

APIChat

  • feeds.newsfilecorp.com

    PharmaCielo Announces Annual General Meeting and Intention to Issue Interest Shares